Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Servier | INDUSTRY |
| Sanofi | INDUSTRY |
| Beshara company | UNKNOWN |
| Kuwait Heart Foundation |
Not provided
Not provided
Not provided
Acute coronary syndrome (ACS) is the most common presentation of Coronary Artery Disease (CAD). It causes significant morbidity and mortality. The Gulf Registry of Acute Coronary Events (Gulf RACE) was conducted in 2007 and filled a wide gap in our understanding of ACS and its management in Kuwait and the Arabian Gulf region. However, the management of ACS has undergone tremendous advances over the last two decades involving pharmacotherapy and device therapy. Practice guidelines have also changed over the last decade. For example, in 2007, there was no catheterization laboratory in any of the general hospitals in Kuwait, primary percutaneous coronary intervention (PCI) was not being practiced, and the rate of in-hospital cardiac catheterization for all ACS patients was very low at around 10%. Currently, of the eight general hospitals in Kuwait, six have catheterization laboratories and five of the six serve as primary PCI centers. There is no contemporary ACS registry in Kuwait, studying its incidence, management, and influence of current changes in clinical practice on patients' outcomes. This multicentre disease-based, country-wide registry is guided by the American Heart Association policy statement for expanding the applications of existing and future clinical registries and the User's Guide published by the Agency for Health care Research and Quality guidance.
This is a prospective, multicentre, country-wide registry of patients who are admitted to any of the eight general hospitals in Kuwait with a diagnosis of ACS over 6-months or more to include 10,000 patients. ACS diagnosis includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina.
The protocol mandates the following basic points:
The Principal Investigator has formed a steering committee and drafted a protocol and case report form (CRF). The steering committee members will meet to finalize the protocol and the CRF. Then an investigators meeting will be held to go over the fine details of the protocol and CRF and to instruct the investigators on how to use the online CRFs.
Data entry will be entered online. Quality Control Surveyors will carry out quality control visits. This will involve the inspection of 5% of the data source (hospital files) of enrolled patients against entered patient data for their accuracy. Centres that are identified to be consistently inaccurate will be warned and might be withdrawn from the registry if necessary. This quality control process will be carried out at 1 month and again at 3 months, from the start of the study. It will later be decided whether other subsequent checks would be required. In addition, the Chief Site Officer (CSO) in each hospital will be required to carry out quality control checks at his/her own hospital. This will involve the random checking of 2 files per week involving checking the online CRF and data source.
The different elements of the form will be filled out prospectively during patient stay in the hospital and subsequently at follow-up. All patients will be followed up for 30 days post ACS.
The registry and data collection will be conducted prospectively with the following objectives:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ACS patients | Patients admitted to hospital with diagnosis of ACS. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Observational registry with no intervention. | Other | No intervention |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | To measure the adverse outcome of in-hospital mortality in ACS patients in Kuwait. | through study completion, an average of 6 months |
| Major Adverse Cardiac Events (MACE) | To measure the in-hospital adverse outcomes like myocardial infarction (MI), cerebrovascular accident (CVA), bleeding, cardiogenic shock, heart failure and others in ACS patients in Kuwait. | through study completion, an average of 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Mortality | To measure the adverse outcome mortality 30 days post discharge in ACS patients in Kuwait. | 30 days from discharge |
| Major Adverse Cardiac Events (MACE) | To measure the adverse outcomes like myocardial infarction (MI), cerebrovascular accident (CVA), bleeding, cardiogenic shock, heart failure and others 30 days post discharge in ACS patients in Kuwait. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
1- Refusal or inability to consent for enrolment
Not provided
Not provided
Not provided
Patients who are admitted to any of the eight general hospitals in Kuwait with a diagnosis of ACS. The sample size will be 10,000 patients. ACS diagnosis includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI) and unstable angina.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Mohammad Zubaid, Professor | Kuwait University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mubarak Al Kabeer hospital | Kuwait City | Kuwait | 13110 | Kuwait |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| 30 days from discharge |
| Rehospitalization | To measure the rehospitalization rate within 30 days post discharge in ACS patients in Kuwait. | within 30 days from discharge |
| Revascularization | To measure the revascularization rate within 30 days post discharge in ACS patients in Kuwait. | within 30 days from discharge |
| Lipid level control | To measure the state of lipid level control at 6 months from ACS event | At 6 months from ACS event |
| Efficacy of lipid lowering agents | To review the types and dosages of lipid lowering agents used. | At 6 months from ACS event |